Evaluating the Stability of Therapeutic Biosimilar Monoclonal Antibodies with Micro-Flow Imaging

Particulate contamination, including protein aggregates, can have an effect on drug safety and efficacy, and characterization of subvisible particles can be an indicator of product and formulation stability. In this App Note, we show how we use µ-Flow Imaging to evaluate the stability of two therapeutic monoclonal antibodies, trastuzumab and bevacizumab, and their biosimilars.